News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News AHA 2020 Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults Shelley Wood November 18, 2020
News Conference News AHA 2019 Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE Yael L. Maxwell November 21, 2019
News Conference News AHA 2018 Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages Michael O'Riordan November 12, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening Michael O'Riordan November 10, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
Presentation AHA 2017 Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Presenter: Kenneth W. Mahaffey November 14, 2017
News Conference News AHA 2014 FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes November 16, 2014